November 2015, Vol. 2, No. 6
Exploring the Possibilities of Manipulating the Immune System to Improve OutcomesLetter to Our Readers
We are pleased to continue our in-depth coverage of the role of immunotherapy in oncology care. Immunotherapy has long captured the interest of researchers combating disease, and none more so than oncology researchers. Recent advances in immunotherapy have made headlines and been the main attraction at association meetings. It is our mission to explore the topic diligently and thoroughly in the hope of providing our readership with information that will help improve and extend the life of patients with cancer.
In this issue, we present an interview with Elizabeth I. Buchbinder, MD, of Dana-Farber Cancer Institute about her research addressing the question of optimal sequencing of immunotherapeutic agents for patients with metastatic melanoma and metastatic renal cell carcinoma. Her research specifically addresses the efficacy and safety of high-dose interleukin-2 given after CTLA-4–targeting agents or other immune checkpoint blockade agents.
We also provide an in-depth article about targeting PD-1 and its ligand PD-L1. It is our hope this report provides increased awareness about the possibilities of manipulating the immune system to effectively combat cancers.
As always, we survey the vast amounts of information coming out of association meetings and bring you relevant and potentially clinically impactful stories. In this issue, you will read about important immuno-oncology information from the European Cancer Congress, American Society of Gene and Cell Therapy, International Lung Cancer Congress, and our own World Cutaneous Malignancies Congress.
Thank you for your loyal readership. We wish you success in your quest to provide the best care for your patients and hope your awareness and understanding of immunotherapy options is enhanced by our offerings.
Sanjiv S. Agarwala, MD
Editor in Chief
Immunotherapy in Oncology
At the 16th Annual International Lung Cancer Congress, Tony Mok, MD, Professor of Clinical Oncology, The Chinese University of Hong Kong, provided an overview of the next generation of agents, taking stock of the recent past for insights into the future of drug discovery. Drug discovery is rarely, if ever, [ Read More ]
Genetic testing in metastatic melanoma should include testing for all actionable mutations in exon 15, said Grant McArthur, MB, BS, PhD, at the 2015 World Cutaneous Malignancies Congress. Testing at the time of disease progression is not yet ready for routine clinical use. Test the Metastases In metastatic melanoma, tumor [ Read More ]